Anti-PD-1 (Toripalimab), Humanized Antibody

CATALOG NO.: A2161-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG4 recombinant monoclonal antibody that binds to programmed death receptor-1 (PD-1) and prevents the interaction with its ligands PD-L1 and PD-L2. This results in the activation of T-cell mediated immune response and inhibits tumor cell growth. The original drug received approval in China in 2018 as the second line of treatment for melanoma. Currently, the drug is evaluated for efficacy and toxicity in Phase I-III clinical trials for nasopharyngeal carcinoma, head and neck squamous cell carcinoma and gastric adenocarcinoma.

ALTERNATE NAMES: JS001, Tab001, PD1, PDCD1, CD279, SLEB2, hPD-1, hPD-I, hSLE1

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human PD-1

CAS NUMBER: 1924598-82-2

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user.

RELATED PRODUCTS:
- Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
- Anti-PD-1 (Sintilimab), Human IgG4 Antibody (A2156)
- Anti-PD-1 (Camrelizumab), Humanized Antibody (A2132)
- Anti-PD-1 (Spartalizumab), Humanized Antibody (A2131)
- Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

FOR RESEARCH USE ONLY! Not to be used on humans.